Multidisciplinary approaches to intrahepatic cholangiocarcinoma

Shishir K. Maithel, T. Clark Gamblin, Ihab R Kamel, Celia Corona Villalobos, Melanie Thomas, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.

Original languageEnglish (US)
Pages (from-to)3929-3942
Number of pages14
JournalCancer
Volume119
Issue number22
DOIs
StatePublished - Nov 15 2013

Fingerprint

Cholangiocarcinoma
gemcitabine
Therapeutics
Drug Therapy
Liver
Hepatic Artery
Standard of Care
Lymph Node Excision
Cisplatin
Hepatocellular Carcinoma
Radiotherapy
Survival Rate
Lymph Nodes
Clinical Trials

Keywords

  • chemotherapy
  • imaging
  • intrahepatic cholangiocarcinoma
  • locoregional
  • multidisciplinary
  • resection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maithel, S. K., Clark Gamblin, T., Kamel, I. R., Corona Villalobos, C., Thomas, M., & Pawlik, T. M. (2013). Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer, 119(22), 3929-3942. https://doi.org/10.1002/cncr.28312

Multidisciplinary approaches to intrahepatic cholangiocarcinoma. / Maithel, Shishir K.; Clark Gamblin, T.; Kamel, Ihab R; Corona Villalobos, Celia; Thomas, Melanie; Pawlik, Timothy M.

In: Cancer, Vol. 119, No. 22, 15.11.2013, p. 3929-3942.

Research output: Contribution to journalArticle

Maithel, SK, Clark Gamblin, T, Kamel, IR, Corona Villalobos, C, Thomas, M & Pawlik, TM 2013, 'Multidisciplinary approaches to intrahepatic cholangiocarcinoma', Cancer, vol. 119, no. 22, pp. 3929-3942. https://doi.org/10.1002/cncr.28312
Maithel, Shishir K. ; Clark Gamblin, T. ; Kamel, Ihab R ; Corona Villalobos, Celia ; Thomas, Melanie ; Pawlik, Timothy M. / Multidisciplinary approaches to intrahepatic cholangiocarcinoma. In: Cancer. 2013 ; Vol. 119, No. 22. pp. 3929-3942.
@article{3a3ad097a3574ccd8fe841366df53f86,
title = "Multidisciplinary approaches to intrahepatic cholangiocarcinoma",
abstract = "After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25{\%} to 35{\%} in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.",
keywords = "chemotherapy, imaging, intrahepatic cholangiocarcinoma, locoregional, multidisciplinary, resection",
author = "Maithel, {Shishir K.} and {Clark Gamblin}, T. and Kamel, {Ihab R} and {Corona Villalobos}, Celia and Melanie Thomas and Pawlik, {Timothy M.}",
year = "2013",
month = "11",
day = "15",
doi = "10.1002/cncr.28312",
language = "English (US)",
volume = "119",
pages = "3929--3942",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "22",

}

TY - JOUR

T1 - Multidisciplinary approaches to intrahepatic cholangiocarcinoma

AU - Maithel, Shishir K.

AU - Clark Gamblin, T.

AU - Kamel, Ihab R

AU - Corona Villalobos, Celia

AU - Thomas, Melanie

AU - Pawlik, Timothy M.

PY - 2013/11/15

Y1 - 2013/11/15

N2 - After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.

AB - After hepatocellular carcinoma, intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy. The etiology of ICC in most patients is not known, but its incidence is on the rise worldwide. There are 3 morphologic subtypes of ICC that can be characterized on cross-sectional imaging, mass forming, periductal infiltrating, and intraductal growth; and the radiographic characteristics of ICC may vary based on the subtype. Complete surgical resection remains the only potentially curative option for patients with ICC. Routine lymphadenectomy at the time of surgical resection should be strongly considered, because lymph node status provides important prognostic information. After surgery, the 5-year survival rate for ICC remains poor at only 25% to 35% in most series. Although numerous clinical trials have been conducted using a variety of chemotherapy regimens to treat ICC, systemic options for ICC remain limited. Doublet gemcitabine and cisplatin therapy is currently considered the standard-of-care first-line therapy for patients with advanced disease. Because ICC is typically confined to the liver and systemic chemotherapy traditionally has had only limited efficacy, there has been increasing interest in locoregional therapy. Although locoregional therapy may include intra-arterial therapies, stereotactic radiotherapy, hepatic artery pump therapy, or ablation, most data are limited. The purpose of this article was to provide a multidisciplinary appraisal of the current therapeutic approaches to ICC.

KW - chemotherapy

KW - imaging

KW - intrahepatic cholangiocarcinoma

KW - locoregional

KW - multidisciplinary

KW - resection

UR - http://www.scopus.com/inward/record.url?scp=84887087327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887087327&partnerID=8YFLogxK

U2 - 10.1002/cncr.28312

DO - 10.1002/cncr.28312

M3 - Article

C2 - 23963845

AN - SCOPUS:84887087327

VL - 119

SP - 3929

EP - 3942

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 22

ER -